Wespiser Mylene @MWespiser

🔗 Full review (open access) frontiersin.org/journals/oncol…

ROS1-positive NSCLC is a heterogeneous disease, with biological diversity influencing response and resistance to targeted therapies. Our review in Frontiers in Oncology provides biological insights linking genomics to treatment decisions. 🔗 Link in comments #ROS1 #NSCLC #LCSM

FIBRONEER-IPF results now online at NEJM!!! Nerandomilast slowed FVC decline at 52 weeks: −114.7 ml (18 mg BID) vs −183.5 ml (placebo) Difference: +68.8 ml (p<0.001) Benefit seen with and without background antifibrotics. #ATS2025

Top 10 GI Trials – ASCO 2025 The biggest GI breakthroughs you must track this year! 🧬 ATOMIC – Atezolizumab + FOLFOX in stage III MSI-H colon 🛡️ MATTERHORN – Durvalumab + FLOT in gastric/GEJ 🧪 DYNAMIC-III – ctDNA-guided chemo in colon 💉 DESTINY-Gastric04 – T-DXd vs RAM+PTX in HER2+ GEJ 🥊 LBA4004 – mFOLFIRINOX vs PAXG in resectable PDAC 🔄 BREAKWATER (Updated) – Encorafenib + Cetuximab in BRAF mCRC ⚔️ ANCHOR – Anlotinib vs Bevacizumab in RAS/BRAF WT mCRC ✅ CheckMate 577 (Updated) – Adjuvant nivo in EC/GEJ 🔬 Actuate 1801 – Elraglusib + nab-Gem in PDAC 🧯 POLCAGB – Chemo vs CRT in gallbladder cancer Do check out the Data at @ASCO #ASCO25 #GIonc #Oncology @OncBrothers @OncoAlert

Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrom... sciencedirect.com/science/articl…

Jaafar's positive view of therapeutic advances that should finally change the prognosis of our SCLC patients after the arrival of 1st-line immunotherapy. @BennounaJaafar @myESMO

keyboard_arrow_left Previous keyboard_arrow_right Next

L'incroyable passage de la flamme olympique à @GustaveRoussy. 🔥 Symbole d'espoir et de résilience, la flamme olympique est passée devant une haie d'honneur composée de patients, de médecins et de soignants de l'institut. ✨ Un évènement unique que nous ne sommes pas prêts d'oublier. ✨ @Paris2024

keyboard_arrow_left Previous keyboard_arrow_right Next

French report on real world 2L outcomes after 1L chemo-immunotherapy for #SCLC @LungCaJournal. Regimens used included platinum rechallenge (PFS 4.6m, OS 8.1m) and lurbinectedin (PFS 2.7m, OS 4.9m), but not meant to compare (selection bias, sens vs res). lungcancerjournal.info/article/S0169-…

Journée IFCT, édition spéciale pour célébrer les 25 ans de l'intergroupe. 1ere partie : l'actualité post #ASCO24, l'avancement de nos #essaiscliniques et une conférence prestige avec les Pr Thierry Le Chevalier et @FordePatrick sur les traitements péri-opératoires.

Looking at ADAURA & LAURA control arms we can wonder whether localized EGFR lung cancer really exists. Multifocal lung extension & mets likely occur very early underlining the need for targeted tt regardless of tumor stage. ctDNA might help to identify the "real" localized ones.

keyboard_arrow_left Previous keyboard_arrow_right Next

Clinical spectrum and evolution of ICIs toxicities over a decade 🔍According to VigiBase data, out of 50,347 reported irAEs 📌Most common irAEs: skin reactions (22.9%), pneumonitis (18.5%), enterocolitis (14.4%), and thyroiditis (12.1%) 📌Most fatal: myocarditis (27.6%) and myasthenia (23.1%) 📌irAE recurrence rate after rechallenge was 28.9% @OncoAlert thelancet.com/journals/eclin…

keyboard_arrow_left Previous keyboard_arrow_right Next

Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions - Cancer Treatment Reviews cancertreatmentreviews.com/article/S0305-…

keyboard_arrow_left Previous keyboard_arrow_right Next

Nanoparticules is a new interesting approach to drug delivery . Lots of advantages. Different types for different targets . 🎯 alliedmarketresearch.com/request-sample…

Targeted therapies in first line for oncogene addicted lung cancer in #France. SOC for some patients (green), pending approval and reimbursement (in orange) and still not accessible (red) outside trials. #JMT24 @IFCTlung

Medicine and Society article by Drs. @Joe_Bruch, @victorroy & @ColleenGrogan5: The Financialization of Health in the United States nej.md/41Qv0XS #HealthPolicy

Should we perform comprehensive genomic analysis of pulmonary large-cell carcinomas? 🔍1426 samples were analyzed; SCLC-like (39%), NSCLC-like (37%), carcinoid-like (2%) and unclassifiable (22%) 📌Among the NSCLC-like group, 5 % of cases had a non-KRAS potentially targetable driver, 9 % of samples harbored KRAS G12C, and 4 % of samples had KRAS G12D mutation @LungCaJournal lungcancerjournal.info/article/S0169-…

keyboard_arrow_left Previous keyboard_arrow_right Next

A lot to digest here! Pan-cancer ADC targets over the past two decades nature.com/articles/s4141… #ADC #ADCtargets #ADChistory

keyboard_arrow_left Previous keyboard_arrow_right Next

NOW OF: In interim analysis of the KEYNOTE-585 ph 3 trial, neoadjuvant and adjuvant pembrolizumab improved pathological complete response versus placebo but not event-free survival in patients with locally advanced gastric or gastro-oesophageal cancer. thelancet.com/journals/lanon…

keyboard_arrow_left Previous keyboard_arrow_right Next

#OpenAccess in Annals of Oncology, results of the ATALANTE-1 RCT investigating OSE2101, a vaccine inducing cytotoxic T lymphocytes against 5 tumor-associated antigens (HER-2, CEA, MAGE 2, MAGE 3 and p53) in HLA-A2+ NSCLC 🫁 after failure of an ICI annalsofoncology.org/article/S0923-… #lcsm

Retrospective report @ClinicalLung of outcomes in #MET exon 14 mutant (n=157) or amplified (n=54) NSCLC. Here, 26.5% had a MET TKI and mOS 25.4m with METex14, mOS 20.6m in MET amp. Would not compare TKI vs non-TKI populations here - too many confounders. clinical-lung-cancer.com/article/S1525-…